Design Therapeutics, Inc. (DSGN)
DSGN moved a median of +0.36% 30 minutes after news, and +0.26% by the close. How DSGN actually reacts to news — the realized, point-in-time move the market made, measured across 157 labeled events over the last three years with zero look-ahead.
DSGN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.11% | 53% | 156 |
| 30-min | +0.36% | 56% | 157 |
| 60-min | +0.45% | 55% | 157 |
| to close | +0.26% | 54% | 156 |
| Middle 50% of DSGN reactions | -1.48% to +1.63% |
|---|---|
| Median reaction (30-min) | +0.36% |
| Measured reactions | 157 |
Half of all Design Therapeutics, Inc. news events land between -1.48% and +1.63% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How DSGN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | +0.65% | 53% | -0.41% |
| Coverage initiations | 11 | +0.19% | 55% | +3.88% |
| Rating reiterations | 12 | +1.00% | 67% | +4.06% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how DSGN ranks against every other measured name →
That’s how DSGN usually reacts — get an email when it moves on news →Email me when DSGN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DSGN's baseline. Nothing else.
Recent DSGN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference | Press release | GlobeNewswire | +1.80% | +1.84% | |
| Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -2.91% | +5.98% | |
| Form 10-Q Design Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.91% | +5.98% | |
| Form 8-K Design Therapeutics, For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | -2.91% | +5.98% | |
| Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 | Press release | GlobeNewswire | -2.46% | +1.54% | |
| Form 8-K Design Therapeutics, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.38% | |
| Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.09% | -4.19% | |
| Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia | Press release | GlobeNewswire | +5.72% | -32.06% | |
| Form 8-K Design Therapeutics, For: May 18 | SEC filing · Form 8-K | SEC EDGAR | +5.72% | -32.06% | |
| Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026 | Press release | GlobeNewswire | +5.72% | -32.06% | |
| Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates | Press release | GlobeNewswire | +15.69% | +21.46% | |
| Form 10-Q Design Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +15.69% | +21.46% | |
| Form 8-K Design Therapeutics, For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | +15.69% | +21.46% | |
| Form ARS Design Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -2.47% | -3.32% | |
| Form DEF 14A Design Therapeutics, For: Apr 23 | SEC filing · Form DEF | SEC EDGAR | -2.47% | -3.32% | |
| Form DEFA14A Design Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -2.47% | -3.32% | |
| Form 8-K Design Therapeutics, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +0.74% | +4.17% | |
| Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates | Press release | GlobeNewswire | +0.38% | -5.22% | |
| Form 10-K Design Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.38% | -5.22% | |
| Form 8-K Design Therapeutics, For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +0.38% | -5.22% | |
| Form S-8 Design Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.38% | -5.22% | |
| Design Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.69% | -1.08% | |
| Form 8-K Design Therapeutics, For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +0.59% | +2.56% | |
| Design Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.21% | -1.37% | |
| Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.00% | +6.68% | |
| Form 10-Q Design Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +6.68% | |
| Form 8-K Design Therapeutics, For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.68% | |
| Design Therapeutics Appoints Justin Gover to Board of Directors | Press release | GlobeNewswire | +2.12% | -2.61% | |
| Form 8-K Design Therapeutics, For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +2.12% | -2.61% | |
| Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference | Press release | GlobeNewswire | +0.00% | -1.12% | |
| Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | -0.25% | +5.68% | |
| Form 10-Q Design Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.25% | +5.68% | |
| Form 8-K Design Therapeutics, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | +5.68% | |
| Form 8-K Design Therapeutics, For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -1.45% | +1.32% | |
| Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 | Press release | GlobeNewswire | +0.38% | +2.76% | |
| Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.00% | +3.36% | |
| Form EFFECT Design Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +2.92% | |
| Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference | Press release | GlobeNewswire | +0.00% | -1.38% | |
| Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results | Press release | GlobeNewswire | +1.51% | +6.67% | |
| Form 10-Q Design Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.51% | +6.67% | |
| Form 8-K Design Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +1.51% | +6.67% | |
| Form S-3 Design Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +1.51% | +6.67% | |
| Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy | Press release | GlobeNewswire | -8.13% | -3.09% | |
| Form DEFR14A Design Therapeutics, | SEC filing · Form DEFR14A | SEC EDGAR | -8.13% | -3.09% | |
| Form ARS Design Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.24% | -7.40% | |
| Form DEF 14A Design Therapeutics, For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | +0.24% | -7.40% | |
| Form DEFA14A Design Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.24% | -7.40% | |
| Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025 | Press release | GlobeNewswire | +0.00% | +8.79% | |
| Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer | Press release | GlobeNewswire | +2.38% | +4.17% | |
| Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results | Press release | GlobeNewswire | +0.31% | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DSGN section they belong to.
Where else DSGN is measured.
DSGN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Design Therapeutics, Inc.'s median reaction calculated?
Every labeled DSGN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 157 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 56% of DSGN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DSGN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.